中国实用内科杂志2025，Vol.45Issue(6)：484-494,11.DOI:10.19538/j.nk2025060106
2型炎症哮喘生物制剂治疗重庆市专家共识
Chongqing expert consensus on biologics treatment for type 2 inflammatory asthma
摘要
Abstract
Severe asthma is a chronic inflammatory disease that seriously affects the life quality of patients.Type 2 inflammation phenotype accounts for a high proportion in patients with severe asthma in China.In the management of type 2 inflammatory asthma,the biologics therapy,as an emerging,targeted therapeutic strategy with significant efficacy,is becoming increasingly important.In response to the lack of experience in the use of biologics by the majority of respiratory physicians in China,the consensus,guided by the 13 clinical questions established through discussions at the expert group meeting,gives expert recommendations on the corresponding issues in terms of drug indications,drug selection,course of drug use,safety,drug combination,and efficacy prediction indicators,in order to help clinicians to improve their levels of decision-making in the use of biologics for asthma,thereby increasing standardized treatment level and control rate of type 2 inflammatory asthma.关键词
重度哮喘/2型炎症哮喘/生物治疗/生物制剂/奥马珠单抗/贝那利珠单抗/美泊利珠单抗/瑞利珠单抗/度普利尤单抗/特泽鲁单抗/专家共识Key words
severe asthma/type 2 inflammatory asthma/biotherapy/biologics/omalizumab/benralizumab/mepolizumab/reslizumab/dupilumab/tezepelumab/expert consensus分类
临床医学引用本文复制引用
《2型炎症哮喘生物制剂治疗重庆市专家共识》制定组,重庆市医师协会呼吸医师分会,重庆市医院协会呼吸内科管理专业委员会,重庆市慢性呼吸系统病防治中心,重庆市呼吸内科医疗质量控制中心,郭述良..2型炎症哮喘生物制剂治疗重庆市专家共识[J].中国实用内科杂志,2025,45(6):484-494,11.基金项目
国家科技部科技创新2030重大项目(2023ZD0506306,2023ZD0506302) （2023ZD0506306,2023ZD0506302）
